Scarica l'app Stockscreener
35.45
0.20%
-0.07
Dopo l'orario di chiusura:
35.48
0.03
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$35.52
Aprire:
$35.79
Volume 24 ore:
1.68M
Relative Volume:
0.61
Capitalizzazione di mercato:
$4.11B
Reddito:
-
Utile/perdita netta:
$-359.64M
Rapporto P/E:
-11.14
EPS:
-3.1831
Flusso di cassa netto:
$-278.69M
1 W Prestazione:
+5.29%
1M Prestazione:
-0.51%
6M Prestazione:
+0.94%
1 anno Prestazione:
+53.40%
Intervallo 1D:
$35.01
$36.79
Intervallo di 1 settimana:
$33.25
$36.79
Portata 52W:
$21.23
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
35.45 | 4.12B | 0 | -359.64M | -278.69M | -3.1831 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-29 | Iniziato | Canaccord Genuity | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
VKTX stock rises after-hours: CNBC flags Viking as likely buyout target this year as big pharma hunts next GLP-1 winner - MSN
Viking Therapeutics, Inc. (VKTX) surpasses market returns: Some facts worth knowing - MSN
Viking Therapeutics (VKTX) barely up since Jim Cramer advised selling the stock - MSN
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo! Finance Canada
Viking Therapeutics, Inc. (VKTX) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Viking Therapeutics rises after Q4 updates on obesity therapy - MSN
(VKTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
VKTX finishes enrollment in second late-stage study on obesity drug - MSN
Is It Too Early To Consider Viking Therapeutics (VKTX) A Bargain After Recent Pullback? - Yahoo Finance
Viking Therapeutics (VKTX) Barely Up Since Jim Cramer Advised Selling The Stock - Insider Monkey
Viking Therapeutics, Inc. (VKTX) latest stock news and headlines - Yahoo Finance UK
20 Stocks Jim Cramer Wanted You To Sell & Immediately Get Out Of - Insider Monkey
Viking Therapeutics to Attend Investor Conferences - Intellectia AI
Viking Therapeutics to Participate at Upcoming Investor Conferences - PR Newswire
MH & Associates Securities Management Corp ADV Buys New Stake in Viking Therapeutics, Inc. - National Today
Viking Therapeutics, Inc. (VKTX) stock price, news, quote and history - Yahoo Finance Singapore
Viking Therapeutics (VKTX) Is Up 7.0% After Completing Enrollment In Key VANQUISH-2 Obesity Trial - Sahm
Viking Therapeutics, Inc. (VKTX) Shares Fall as Broader Market Rises: Important Details - Bitget
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Latest Stock News & Headlines - Yahoo Finance
Viking Therapeutics Inc (1VT.HM) Interactive Stock Chart - Yahoo! Finance Canada
Viking Therapeutics, Inc. (VKTX) interactive stock chart - Yahoo Finance Singapore
Where Will Viking Therapeutics Stock Be in 10 Years? - The Globe and Mail
Where Will Viking Therapeutics Stock Be in 10 Years? - The Motley Fool
Did VK2735’s VANQUISH-2 Enrollment Milestone Just Reframe Viking Therapeutics' (VKTX) Obesity Drug Ambitions? - Yahoo Finance
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - stocktwits.com
Viking Therapeutics (VKTX) stock has failed to impress since Jim Cramer expressed caution - MSN
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How (VKTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today - Sahm
[ARS] Viking Therapeutics, Inc. SEC Filing - Stock Titan
[DEF 14A] Viking Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Viking Therapeutics, Inc. (VKTX) declines more than market: Some information for investors - MSN
43,152 Shares in Viking Therapeutics, Inc. $VKTX Purchased by Royal Fund Management LLC - MarketBeat
2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More - AOL.com
A Look At Viking Therapeutics (VKTX) Valuation As VANQUISH 2 Enrollment Milestone Advances VK2735 Program - Sahm
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors - Yahoo Finance Singapore
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):